Sentinel Node and Ovarian Tumors: A Series of 20 Patients

Nyberg, Reita; Korkola, Pasi; Mäenpää, Johanna

doi:10.1097/igc.0000000000000948

Cited by 29 publications

(39 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few studies have described a feasible approach to sentinel node mapping in patients with ovarian cancer. [16][17][18][19][20][21] Unlike vulvar, cervix, and endometrial cancer, where the injection site is readily accessible before surgical prepping, the ovary is much more difficult to access. Among the challenges of where, when, and what to inject, is the equally inconvenient procedural step of needing to remove the clinically suspicious ovary before confirming that it has a malignancy, prompting the need to perform sentinel node mapping.…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, the technical complexity and risk of tumor dissemination associated with the injection of tracers into the cortex 16 17 have limited the published experience to few studies with a small sample of patients, most not involving malignant ovarian tumors. [16][17][18][19][20][21][22][23] The objective of this study was to prospectively delineate any major safety concerns related to our proposed sentinel lymph node technique and assess its feasibility in patients with clinical stage I-II ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial

Lago

Belló

Montero

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectiveEarly-stage ovarian cancer might represent an ideal disease scenario for sentinel lymph node application. Nevertheless, the published experience seems to be limited. Our objective was to assess the feasibility and safety concerns of sentinel lymph node biopsy in patients with clinical stage I–II ovarian cancer.MethodsWe conducted a prospective cohort study of 20 patients with histologically confirmed ovarian cancer. 99mTc and indocyanine green were injected into both the utero-ovarian and infundibulopelvic ligament stump, if they were present, during surgical staging. An intraoperative gamma probe and near-infrared fluorescence imaging were used to detect the sentinel lymph nodes. Inclusion criteria included: >18 years of age, suspicious adnexal mass (unilateral or bilateral) at ultrasound and CT imaging or confirmed ovarian tumor after previous surgery (unilateral or bilateral salpingo-oophorectomy with or without hysterectomy). Adverse events were recorded through postoperative day 30. The primary trial end point was to report adverse events related to the technique, including the use of 99mTc and ICG intraperitoneally, as well as the feasibility of the technique.ResultsA total of 20 patients were included in the analysis. Sentinel lymph nodes were detected in 14/15 (93%) pelvic and all 20 (100%) para-aortic regions. Five patients did not have utero-ovarian injection because of prior hysterectomy. The mean time from injection to sentinel lymph node resection was 53±15 min (range; 30–80). The mean number of harvested sentinel lymph nodes was 2.2±1.5 (range; 0–5) lymph nodes in the pelvis and 3.3±1.8 (range; 1–7) lymph nodes in the para-aortic region. There were no adverse intraoperative events, nor any within the 30 days of follow-up related with the technique.ConclusionSentinel lymph node mapping in early-stage ovarian cancer is feasible without major intraoperative or < 30 days safety concerns. (NCT03452982).Trial registration numberClinicalTrials.gov, NCT03452982.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial

Lago

Belló

Montero

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Many studies have evaluated the feasibility of detecting SLNs by injecting tracer(s) into the mesovarium and/or ovarian ligaments. Tracer injection prior to tumor resection and examination by frozen sections resulted in very high detection rates (87.5-100%) of at least one SLN (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) . The present study showed that injection of tracer into the remains of both ovarian ligaments after resection of the pathological adnex resulted in a low rate of SLN detection (3 out of 11 patients, 27%; CI 10-53%).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have described the feasibility of the SLN technique in patients with early-stage EOC (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) . Most recent studies utilized a method in which a tracer is injected into the ovarian ligaments prior to tumor resection, with nearly all of these studies reporting very high detection rates (71-100%…”

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?

Laven

Kruitwagen

Zusterzeel³

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: Sentinel lymph node (SLN) detection in ovarian cancer is feasible when tracers are injected before the pathological ovary is resected. This study aims to investigate whether the SLN identification is also feasible in patients whose ovarian tumor has already been resected with injection of the tracer into the ovarian ligaments stumps, i.e. in the event that a frozen section confirms malignancy. Methods: Patients who underwent laparotomy with frozen section confirming an ovarian malignancy, and those who underwent a second staging laparotomy after prior resection of a malignant ovarian mass, were included. Blue dye and a radioactive isotope were injected in the stumps of the ligamentum ovarium proprium and the ligamentum infundibulo-pelvicum. After an interval of at least 15-minutes, the sentinel node(s) were identified using either the gamma-probe and / or blue dye.Results: A total of 11 patients were included in the study, the sentinel node (SLN) procedure was completed in all 11 patients. At least one SLN was identified in 3 patients, resulting in a rather low detection rate of 27,3%. Conclusion: In this study we showed that SLN procedure after (previous) resection of the tumor seems inferior to detect sentinel nodes when compared to injection of the tracer in the ovarian ligaments before tumor resection.Trial registration on clinical trials: NCT02540551 https://clinicaltrials.gov/ct2/show/NCT02540551

show abstract

“…W e have read with great interest the article of Nyberg et al, 1 which was recently published in the International Journal of Gynecological Cancer. They reported the results of lymphatic mapping and sentinel node biopsy in 20 patients with ovarian tumors and concluded that sentinel node biopsy is feasible in these tumors.…”

mentioning

confidence: 99%

Feasibility of Sentinel Node Mapping in Ovarian Tumors

Sadeghi

2018

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Sentinel Node and Ovarian Tumors: A Series of 20 Patients

Cited by 29 publications

References 9 publications

Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial

Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial

Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?

Feasibility of Sentinel Node Mapping in Ovarian Tumors

Contact Info

Product

Resources

About